Zoetis announced today it has received expanded label approval from the Food and Drug Administration’s Center for Veterinary Medicine (CVM) on three beef implant products. Synovex Choice® is the foundation of new reimplant labels that are now available to feedlot operations, which also include Synovex Plus® and Synovex® One Feedlot.
“This approval provides beef producers with enhanced flexibility to more broadly use these technologies to help them meet their production and profitability goals,” said John Hallberg, DVM, PhD, U.S. director of regulatory affairs, Zoetis. “The performance benefits of Synovex Choice, Synovex Plus and Synovex One Feedlot have long been proven and this is the logical next step for the industry.”
These three products are approved for reimplanting programs in both steers and heifers fed in confinement for slaughter. The three reimplantation labels include:
• Synovex Choice followed by Synovex Choice, 60 to 120 days later
• Synovex Choice followed by Synovex Plus, 60 to 120 days later
• Synovex Choice followed by Synovex One Feedlot, 60 to 120 days later
Effective immediately, existing packages of Synovex Choice, Synovex Plus and Synovex One Feedlot can be used in reimplanting programs at feedlots. Animal health product suppliers and cattle producers will begin seeing updated labels with the approved reimplantation language by the end of 2022.
“The Synovex brand has contributed more than 66 years of growth productivity and innovation to the U.S. beef cattle industry,” said Paul Parker, senior marketing manager, Zoetis. “We recognized the need and committed our resources to seek approval for these reimplant labels. These new label indications provide cattle feeders with proven options to help optimize performance in a profitable and sustainable manner.”
For more information on how the expanded labels will fit your operation, please visit with your Zoetis sales representative. You also can visit www.Synovex.com to learn more.
Refer to individual labels for complete directions for use, precautions, and warnings. Reimplant only if and as directed in labeling.
As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After 70 years innovating ways to predict, prevent, detect and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide, from livestock farmers to veterinarians and pet owners. The company's leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $7.8 billion in 2021 with approximately 12,100 employees. For more, visit zoetis.com.